Abstract Apolipoprotein (apo) E phenotype is an important genetic determinant of plasma low-density lipoprotein (LDL) cholesterol and apo B levels. We have determined apo E phenotype by isoelectric focusing and plasma lipid, lipoprotein cholesterol, apo A-I, apo B, and lipoprotein(a) levels, as well as LDL particle size, in 2258 men and women participating in the Framingham Offspring Study. Apo E phenotype (E2/2, E2/4, E3/2, E3/3, E3/4, and E4/4) was not associated with plasma lipoprotein(a) levels but was associated with plasma LDL cholesterol levels, apo B levels, and LDL size in men and with plasma total cholesterol, LDL cholesterol, and apo B levels in women. The average effect of the e2 allele was to lower plasma LDL cholesterol levels by 9.2 mg/dL in men and by 13.7 mg/dL in women, while the average effect of the e4 allele was to increase LDL cholesterol levels by 2.6 mg/dL in men and by 5.4 mg/dL in women. When men were divided into two groups according to their age (<50 and ^50 years old), the average effect of the e2 allele was to lower plasma levels of LDL cholesterol by 10.2 mg/dL in younger men and by 7.5 mg/dL in older men. In premenopausal women, the average D ue to the high incidence of coronary heart disease (CHD) in Western society, numerous efforts have been aimed at identifying both environmental and genetic factors that may be related to its development. Apolipoprotein (apo) E phenotype has been proposed as an important genetic determinant of CHD because of the association between apo E phenotype and plasma total and low-density lipoprotein (LDL) cholesterol levels.
effect of the e2 allele was to lower LDL cholesterol by 8.2 mg/dL and, in postmenopausal women, by 20.4 mg/dL. An opposite effect of the e4 allele was observed: the e4 allele was associated with increases in plasma LDL cholesterol levels of 4.0 mg/dL in younger men and of 1.0 mg/dL in older men. The e4 allele was associated with increases in plasma LDL cholesterol levels of 1.6 mg/dL in premenopausal women and of 7.1 mg/dL in postmenopausal women. The apo e locus explained 1.0% of the variance in LDL cholesterol levels in men and 2.1% in women. However, only 0.5% of the LDL cholesterol level variance was due to variation at the e locus in premenopausal women, whereas 5.0% of the LDL cholesterol level variance was explained by apo E polymorphism in postmenopausal women. Our data indicate that the association of apo E phenotype with LDL cholesterol levels is significantly greater in postmenopausal women than in premenopausal women or apo E4 differ from the more frequent apo E3 isoform by a single amino-acid substitution due to a single point mutation, conferring a more acidic (E2: Argl58->Cys) or more basic (E4: Cysll2-»Arg) charge to the protein.
Since the e alleles are expressed in a codominant fashion, six different phenotypes are observed in the general population: E2/2, E3/3, E4/4, E3/2, E3/4, and E4/2.
When compared with the apo E3 isoform, apo E2 has a markedly reduced affinity (<1%) for the LDL receptor. 14 In most E2/2 homozygotes, this results in only a modest accumulation of cholesterol-enriched lipoprotein remnants of both hepatic and intestinal origin, or /J-VLDL, which is not sufficient to cause an elevation of plasma cholesterol and triglyceride levels above normal. However, in individuals with predisposing genetic, hormonal, or environmental factors, this phenotype is associated with type III hyperlipoproteinemia or dysbetalipoproteinemia. On the other hand, the apo E4 isoform, although exhibiting normal binding to the LDL receptor, has greater affinity for VLDL and chylomicrons than apo E3, which may result in enhanced liver uptake of these lipoproteins and downregulation of the LDL receptor. 15 " 17 The present study was undertaken to determine the association between apo E phenotype and plasma lipid and lipoprotein levels in a well-characterized North American population. In this population, we have de- .02* Apo indicates apolipoprotein; TC, total cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglyceride; and Lp(a), lipoprotein(a).
*ANCOVA: all Upld and lipoprotein parameters were adjusted for age and body mass index, with the exception of LDL particle score, which was adjusted for plasma TG level, age, and body mass index.
tPercentage of participants with LDL cholesterol levels a 160 mg/dL. + * 2 test.
termined the frequency of the three common e alleles by age and sex. Our results confirm previous studies indicating that the presence of apo E2 is associated with lower plasma levels of LDL cholesterol and apo B and that apo E4 is associated with higher levels of these plasma parameters. However, the effect of apo E phenotype on LDL cholesterol and apo B levels is considerably greater in postmenopausal women than in premenopausal women or in men.
Methods Population
Of the 1764 men and 1805 women who participated in the third examination cycle of the Framingham Offspring Study, 18 complete plasma lipid, VLDL isolation by ultracentrifugation, and apo A-I and B measurements and apo E characterization were available in a total of 1123 men (age range, 23 to 77 years; mean age, 49±10 years) and 1135 women (age range, 19 to 78 years; mean age, 49±10 years). All subjects were white. Women were defined as postmenopausal if they had not had menses in the past 12 months.
Apo E Isoforms
Each subject's apo E phenotype was determined from VLDL separated from plasma. VLDL samples were isolated by ultracentrifugation in a Beckman 50 Ti rotor at 39 000 rpm for 18 hours at 4°C, at a d=1.006 g/mL. Isolated VLDL samples were lyophilized, delipidated, and subjected to isoelectric focusing (IEF) within a pH range of 4.0 to 6.5. The detailed procedure for the characterization of apo E isoforms from IEF gels has been previously described by Ordovas et al. 
Lipid and Lipoprotein Analyses
Blood was drawn from each subject after a 12-to 14-hour overnight fast and collected into tubes containing 0.1% EDTA. For the measurement of plasma HDL cholesterol, apo B-containing lipoproteins were precipitated by the dextran sulfate-Mg 2+ method. 19 Plasma total cholesterol, 1.006 g/mL infranatant cholesterol, HDL cholesterol, and triglyceride levels were measured by automated enzymatic techniques with an Abbott Diagnostic ABA-200 bichromatic analyzer. 20 Plasma VLDL cholesterol and LDL cholesterol values were then obtained as follows: VLDL cholesterol equals total cholesterol minus 1.006 g/mL infranatant cholesterol; and LDL cholesterol equals 1.006 g/mL infranatant cholesterol minus HDL cholesterol. The Friedewald formula, which is commonly used in clinical practice to estimate plasma LDL cholesterol levels, was also used: LDL cholesterol equals total cholesterol minus (triglycerides/5 plus HDL). 21 Our laboratory participates in the Centers for Disease Control and Prevention (CDC) lipid standardization program. Coefficients of variation between runs for all lipid assays were less than 5%.
LDL particle size was determined by 2% to 16% nondenaturing gradient polyacrylamide gel electrophoresis of whole plasma, as previously described. 22 Since it has been shown that each individual may exhibit from one to three LDL bands, LDL particle size was expressed as LDL particle score, which takes into account all LDL bands in a proportional manner. 23 Plasma apo B and apo A-I levels were measured by noncompetitive enzyme-linked immunosorbent assays. 24 
Statistical Analyses
The SAS statistical program (SAS Institute) was used to perform statistical analyses. Rare apo E phenotypes (El, E5) *ANCOVA: all lipld and lipoprotein parameters were adjusted for age, body mass index, and menopausal status, with the exception of LDL particle score, which was adjusted for plasma TG level, age, body mass index, and menopausal status.
tPercentage of participants with LDL cholesterol levels a 160 mg/dL + * 2 test.
were excluded from the analyses. Allele frequencies at the e locus were estimated by the gene-counting method. A x 2 test (df=3) was used to determine whether the observed apo E phenotype frequencies were in agreement with the expected apo E phenotype frequencies determined by the HardyWeinberg law. Differences in apo e allele frequency were assessed by x 2 analysis (df=2). A logarithmic transformation was applied to plasma triglyceride and VLDL cholesterol values before analysis because of their skewed distribution. Mean plasma lipid, lipoprotein, and apolipoprotein levels were compared across categories of apo E phenotype (E2/2, E2/4, E3/2, E3/3, E4/3, and E4/4 phenotypes) using ANCOVA to adjust for age and body mass index (BMI) effects in men and age, BMI, and menopausal status effects in women. LDL particle score was adjusted for plasma triglyceride levels, age, and BMI (and menopausal status in women). In all analyses, a value of P<.05 was considered statistically significant. The average effect (a) of the e2, e3, and e4 alleles on plasma total cholesterol, LDL cholesterol, and apo B levels (adjusted for age and BMI in men and age, BMI, and menopausal status in women) was determined as follows 25 :
where f-a, f^, etc, are the expected phenotype frequencies assuming Hardy-Weinberg equilibrium; fa,/*, and/,* are the allele frequencies; ^22. M23. etc, are the adjusted (for age and BMI) means for the phenotype, and /x is the grand mean of the sample. The unbiased contribution of the apo E polymorphism to the variability of LDL cholesterol was assessed using the following formula, as previously described 26 :
where; is the genotype at the e locus ( 1 . . . / ) , /A is equal to £ fa, and 4> 2 is the within-class variance. j=\
Results
The frequency of the different apo E phenotypes in our population was in Hardy-Weinberg equilibrium (men, * 2 =6.1, NS; women, * 2 =6.7, NS).
Plasma lipid, lipoprotein, and apolipoprotein levels in 1123 men and 1135 women with different apo E phenotypes are shown in Tables 1 and 2 , respectively. Plasma LDL cholesterol and apo B levels were significantly different in subjects with different apo E phenotype, in both men and women. The age-, BMI-, and plasma triglyceride-adjusted LDL particle scores were also significantly different in men with different apo E (Table 1) . Interestingly, in both men and women apo E phenotype was not associated with plasma lipoprotein(a) [Lp(a)] concentrations (Tables 1  and 2 ).
To determine whether the observed associations between apo E phenotype and plasma lipid levels were affected by age, male subjects were divided into two groups: participants aged <50 years (mean age, 41 ±6 years) and participants aged ^50 years (mean age, 58±5 years). Women also were divided into two groups, based on their menopausal status: premenopausal (mean age, 42 ±7 years) and postmenopausal women (mean age, 57 ±7 years). In men, LDL cholesterol and apo B levels were marginally associated with apo E phenotype in younger and older subjects (Table 3) . In women, after exclusion of subjects taking sex hormones (estrogen or estrogen/progestin combinations: 22 premenopausal women and 57 postmenopausal women), plasma cholesterol, LDL cholesterol, and apo B levels were significantly associated with apo E phenotype only in the postmenopausal group (Table 4) . Only apo B levels were significantly associated with apo E phenotype in postmenopausal women on estrogen replacement therapy (Table 5 ) (only one subject was present in the E4/4 and E4/2 categories).
The average effect of the e2 allele was to reduce plasma levels of total cholesterol, LDL cholesterol, and apo B by 5.0 mg/dL, 9.2 mg/dL, and 4.5 mg/dL, respectively, in men and by 13.7 mg/dL, 13.7 mg/dL, and 11.0 mg/dL, respectively, in women (Figure) . The average effect of the e4 allele was to increase these plasma parameters by 2.6 mg/dL, 2.6 mg/dL, and 5.7 mg/dL, respectively, in men and by 6.7 mg/dL, 5.4 mg/dL, and 4.5 mg/dL, respectively, in women. The effect of the e3 allele was negligible (range, -0.8/+0.2 mg/dL) in this population (Figure) . While the average effect of e alleles was similar in younger and older men, the impact of both e2 and e4 alleles was much more evident in postmenopausal women than in premenopausal women not taking estrogens (Figure) .
The apo E locus accounted for 1.0% of the variability of LDL cholesterol levels in men and 2.1% of the variability of LDL cholesterol levels in women. In men younger and older than 50 years, apo E polymorphism contributed 0.9% and 0.2%, respectively, of the variability of plasma LDL cholesterol levels. After the exclusion of subjects taking estrogens, 0.5% and 5.0% of the variability of plasma LDL cholesterol were explained by apo E polymorphism in premenopausal and postmenopausal women, respectively.
The e allele frequency in men, according to age, and in women, according to menopausal status, is shown in Table 6 . No difference in apo e allele distribution between men and women (;^2=0.6, NS) was observed. A nonsignificant trend toward lower e4 frequency in older men versus younger men (-12%, ^2=1.5) and particularly in postmenopausal women versus premenopausal women ( -16%, ^2=2.3) was observed.
Discussion
The association between apo E polymorphism and plasma LDL cholesterol and apo B levels that we have observed in both men and women in the Framtngham Offspring population is in agreement with studies car- Apo indicates apolipoprotein; TC, total cholesterol; and LDL-C, low-density lipoprolein cholesterol.
*ANCOVA (parameters were adjusted for age and body mass index).
ried out on several different populations.
1 -727 -30 Table 7 summarizes the results of our study and some of the previous studies. It has been postulated that the association of apo E2 and E4 isoforms with LDL cholesterol levels is partly mediated through the LDL receptor. 61517 In individuals homozygous for the apo E2 isoform, low LDL cholesterol levels have been reported to be associated with both a decreased conversion of VLDL to LDL and an accelerated catabolism of LDL particles. 3134 This latter effect is mediated by two mechanisms: (1) the upregulation of the LDL receptor due to the lower intracellular cholesterol availability associated with the deficient uptake of remnants and (2) the increased availability of the hepatic LDL receptors due to the lack of competition for binding by chylomicron and VLDL remnants. This same mechanism acts to M a n lower LDL cholesterol and apo B levels in apo E2 heterozygotes, whose plasma LDL cholesterol and apo B levels are intermediate between apo E2 and apo E3 homozygotes. In apo E4 subjects, LDL catabolism is reduced because of lower activity of the LDL receptor. 34 Our study shows that the overall effect of the apo E phenotype on LDL cholesterol and apo B levels is greater in women than in men. This is in contrast to the results of a study in a very young population in Finland (aged 3 to 18 years), which showed a stronger impact of apo E phenotypes on total cholesterol, LDL cholesterol, and apo B levels in males than in females. 35 The difference in the age of the participants in our study and in the Finnish study may be responsible for this discrepancy, since, as discussed below, the hormonal profile in women seems to modulate the effect of the apo E phenotype.
While differences in plasma LDL particle levels were observed in subjects with different apo E phenotype in both younger men (LDL cholesterol, P<.04) and older men (apo B, P<.Q5), in women differences in plasma LDL cholesterol and apo B levels between different apo E phenotypes were limited to postmenopausal women only. This finding suggests a role of sex hormones in the expression of the apo E phenotype-related differences in LDL cholesterol and apo B levels. Previous studies have shown that sex hormones modulate the impact of apo E2 on plasma lipoprotein metabolism, so that the expression of the clinical and laboratory signs of type III hyperlipoproteinemia are more frequent in men than in women and, when present in women, they occur mostly after menopause. 3637 Estrogens mediate an upregulation of the hepatic LDL receptor 38 and therefore increase the removal of LDL particles. 39 Postmenopausal women have higher LDL cholesterol levels than premenopausal women, even after the effect of age on LDL cholesterol is taken into account. 40 Estrogen replacement treatment has been shown to markedly decrease LDL cholesterol in postmenopausal women. 394142 In postmenopausal women, the presence of the e2 allele in single or double copy may significantly contribute to maintaining an accelerated LDL catabolism and lowering LDL cholesterol and apo B levels. On the other hand, postmenopausal women with the apo E3 or E4 isoform cannot compensate in this manner, and LDL receptor activity is downregulated because of the decrease in estrogen production, so that marked differences in LDL cholesterol levels may arise between postmenopausal women with different apo E phenotype. The modulation of the association of apo E phenotype with LDL cholesterol levels by estrogens is also illustrated by the greater contribution of apo e locus to LDL cholesterol variability in postmenopausal women than in premenopausal women. The association of apo E phenotype with plasma LDL cholesterol levels in postmenopausal women undergoing sex hormone replacement therapy was not significant. However, the sample size was small. In addition, women taking estrogen or estrogen/progestin combinations were included in this group, and it has been shown that estrogen/ progestin combinations do not significantly alter the LDL production and catabolism rates, 43 while estrogens alone significantly increase LDL catabolism rate. eride-rich lipoproteins of both intestinal and liver origin, accompanied by delayed clearance of apo B-100, apo B-48, and apo A-IV within triglyceride-rich lipoproteins. 44 ' 45 A similar but less striking pattern has been observed in apo E2 homozygous patients. 45 One criterion for dysbetalipoproteinemia in type III hyperlipoproteinemia is a ratio >0.3 of VLDL cholesterol to triglyceride. Such a ratio was observed in our subjects with apo E2/2 phenotype if they were postmenopausal women or men over 50, suggesting an age effect. However, the number of subjects with E2/2 phenotype was very small.
Our study clearly indicates that Lp(a) levels are not influenced by apo E phenotype. The catabolic pathway of Lp(a) particles is not yet well known. Based on findings that Lp(a) levels are higher in subjects with genetic defects of the LDL receptor (familial hypercholesterolemia) than in normolipidemic subjects, 46 ' 47 and that Lp(a) is rapidly metabolized in transgenic mice overexpressing the LDL receptor, 48 it has been suggested that part of the plasma pool of Lp(a) may be metabolized through the LDL receptor. However, treatment of hypercholesterolemia with hydroxymethylglutaryl coenzyme A reductase inhibitors or with anion exchange resins, which have been shown to upregulate the LDL receptor, is not associated with any change in plasma Lp(a) levels. 49 De Knijff et al 50 have shown in 303 subjects that Lp(a) levels were influenced by the apo E phenotype in a manner similar to that of LDL cholesterol. Our results in a much larger population clearly indicate that Lp(a) is not influenced by the apo E phenotype and are in agreement with the findings of Sandkamp et al 51 in 337 myocardial infarction survivors, which show that Lp(a) levels are not influenced by apo E phenotype despite a significant effect of this parameter on apo B.
In both men and women, there was a trend toward smaller LDL particles from the E2 to the E4 subjects (a larger LDL particle score reflects a smaller LDL particle). The difference in LDL particle score was statistically significant only in men, after LDL particle score was adjusted for plasma triglyceride level, which has been shown to be a strong predictor of LDL particle size. 22 Our study, the largest to date to determine the apo E phenotype in a male and female population, indicates that the relative frequency of the e alleles is very similar in men and women. However, when men and women were divided into two groups, based on their age and menopausal status, respectively, we observed in both men and women a tendency toward lower e4 allele frequency with age, especially in women. Even though this trend was not statistically significant, the frequency of the e4 allele in postmenopausal women was 16% lower than in premenopausal women, and in older men it was 12% lower than in younger men. Previous studies have indicated that the frequency of the e4 allele in octogenarians was lower than in younger subjects (mean age, 36 years) and that this difference was statistically significant only in women. 52 Similar findings have been reported in other populations of women. 53 - 54 These reports, consistent with our results, suggest that the e4 allele may represent a risk factor for premature death, especially in women. The cause of selection associated with apo E4 isoform is not known, but with the exception of one study 55 there are indications that apo E4 may be more frequently associated with myocardial infarction than other apo E isoforms. 56 ' 57 The lower frequency of the e4 allele in older subjects, which is more evident in women than in men, could be related to the stronger impact of the E isoforms in postmenopausal women than in older men. Our results indicate that the sharp increase in LDL cholesterol levels occurring in women after menopause may be accentuated by the presence of the E4 isoform. In fact, menopause in women with the E3/2, E3/3, and E3/4 phenotype was associated with a 9%, 21%, and 26% increase, respectively, in LDL cholesterol levels. Recently, a linkage between lateonset familial and sporadic Alzheimer's disease and the apo E4 isoform has been discovered. 58 This association could explain part of the negative selective survival associated with the presence of the E4 isoform, especially in elderly populations.
In this study we provide evidence that the impact of the apo E phenotype on plasma LDL particles is influenced by sex. In women, menopause is associated with a greater effect of the e2 and e4 alleles on LDL cholesterol and apo B levels, suggesting that sex hormones can modulate the impact of the apo E phenotype on these plasma parameters. In addition, our results provide evidence that apo E phenotype does not influence plasma Lp(a) levels.
